Scientific Program
| Time | Topic Session |
| 12:30pm-6:00pm |
Registration Sign-In |
| 6:45pm-7:00pm |
Opening RemarksAlphonse E. Sirica, Ph.D., M.S. (VCU) |
SESSION 1: Hepatobiliary Cancer Risk Conditions and Prevention Strategies
Chairs: Anna Mae Diehl, M.D., Hashem B. El-Serag, M.D., M.P.H.
Key Topic Areas: Focus on known risk conditions for primary liver cancers, with added emphasis on prevention strategies.
| Time | Presentation Title and Speaker* Ϯ |
| 7:00pm-7:30pm |
The changing etiology of liver cancer, challenges for the next 20 yearsJohn D. Groopman, Ph.D. (Johns Hopkins) |
| 7:30pm-8:00pm |
Prevention of hepatitis C related hepatocellular carcinomaHashem B. El-Serag, M.D., M.P.H. (Baylor College of Medicine) |
| 8:00pm-8:30pm |
Liver repair and risk for liver cancerAnna Mae Diehl, M.D. (Duke) |
| 8:30pm-8:45pm |
Refreshment Break |
| 8:45pm-9:15pm |
Steatohepatitis accelerates HCC development in miceGyongyi Szabo, M.D., Ph.D. (UMass) |
| 6:30am-7:45am |
Conference Continental Breakfast |
SESSION 2: Molecular Signaling Pathways, Pathogenesis, and Hepatic Oncogenesis
Chairs: Lopa Mishra, M.D., George K. Michalopoulos, M.D., Ph.D.
Key Topic areas: Focus on dysregulated signaling, cellular and molecular pathogenesis, and metabolic pathways relevant to hepatobiliary cancer development and progression.
| Time | Presentation Title and Speaker* Ϯ |
| 8:00am-8:30am |
Cellular dynamics and signaling pathways linking liver regeneration to hepatocarcinogenesisGeorge K. Michalopoulos, M.D., Ph.D. (Univ. Pittsburgh) |
| 8:30am-9:00am |
How does HCC develop in an inflamed, steatotic and fibrotic liver?Jian Wu, M.D., Ph.D. (Fudan Univ. Shanghai Medical College) |
| 9:00am-9:30am |
Modeling human HCC in mice: biological and therapeutic implicationsPaul Monga, M.D. (Univ. Pittsburgh) |
| 9:30am-9:45am |
Refreshment Break |
| 9:45am-10:15am |
Evidence for cancer stem cells and altered TGF-β stem niche in hepatocarcinogenesisLopa Mishra, M.D. (George Washington Univ.) |
| 10:15am-10:45am |
Mechanisms of invasiveness in cholangiocarcinoma: a potential therapeutic targetMario Strazzabosco, M.D., Ph.D. (Yale Univ.) |
| 10:45am-11:15am |
Membrane cytoskeletal dynamics in hepatobiliary tumor metastasisMark A. McNiven, Ph.D. (Mayo) |
| 11:15am-11:45am |
IDH mutant cholangiocarcinomaNabeel M. Bardeesy, Ph.D. (Mass General, Harvard) |
| 12:00pm-1:15pm |
Conference Lunch |
SESSION 3: Microenvironment and Hepatobiliary Cancer Progression
Chairs: Gregory J. Gores, M.D., Scott L. Friedman, M.D.
Key Topic Areas: Focus on current mechanism-based studies aimed at elucidating the origins, cellular and molecular interactions, tumor promoting effects, prognostic implications, and therapeutic potential of targeting cancer-associated fibroblasts in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
| Time | Presentation Title and Speaker* Ϯ |
| 1:30pm-2:00pm |
Fibrotic stromal links to liver carcinogenesisScott Friedman, M.D. (Mount Sinai) |
| 2:00pm-2:30pm |
Hepatic stellate cells and hepatocellular carcinomaRobert F. Schwabe, M.D. (Columbia Univ.) |
| 2:30pm-3:00pm |
Modeling the desmoplastic stromal of intrahepatic cholangiocarcinoma for therapeutic targetingAlphonse E. Sirica, Ph.D., M.S. (VCU) |
| 3:00pm-3:15pm |
Refreshment Break |
| 3:15pm-3:45pm |
Targeting cancer-associated fibroblasts for the treatment of cholangiocarcinomaGregory J. Gores, M.D. (Mayo) |
| 3:45pm-4:15pm |
Transcriptomic dissection of liver cancer risks in cirrhosisYujin Hoshida, M.D., Ph.D. (Mount Sinai) |
| 4:15pm-4:30pm |
Hepatocyte-specific deletion of Tristetraprolin family of RNA binding proteins result in the development of hepatocellular carcinomasSonika Patial, Ph.D. (Louisiana State Univ.) |
| 4:30pm-4:45pm |
Notch2 controls hepatocyte-derived cholangiocarcinoma formation in miceJingxiao Wang, M.D. (Univ. California-San Francisco) |
| 5:30pm-7:30pm |
Early Investigator Meet and Greet Reception(includes heavy Hors doeuvres and beverages) |
| 7:45pm-9:45pm |
Early Career Investigator Poster SessionThis session is abstract driven and will be used to highlight research by early career investigators. Posters will be available for viewing throughout the days of December 8 and 9, with attendance by the presenters required during the full two hour time period of the Early Career Investigator Poster Session. |
| 6:30am-7:45am |
Conference Continental Breakfast |
SESSION 4: MicroRNAs in Hepatobiliary Cancer Growth, Progression, and Therapy
Chairs: Gianfranco D. Alpini, Ph.D., Florin M. Selaru, M.D., M.B.A.
Key Topic areas: Focus on the involvement of deregulated microRNAs on oncogenic pathways in primary liver cancers and their potential as therapeutic targets for hepatocellular and cholangiocellular carcinomas.
| Time | Presentation Title and Speaker* Ϯ |
| 8:00am-8:30am |
Role of the miR-34a-dependent clock gene, Per1, in the regulation of cholangiocarcinoma growthGianfranco Alpini, Ph.D. (Baylor Scott & White, Texas A&M, Central Texas Veterans Health Care System) |
| 8:30am-9:00am |
Argonaute CLIP defines a deregulated miR-122 bound transcriptome that predicts patient survival in human liver cancerKalpana Ghoshal, Ph.D. (Ohio State Univ.) |
| 9:00am-9:30am |
Epigenetic regulation of miRNAs in liver cancersTong Wu, M.D., Ph.D. (Tulane Univ.) |
| 9:30am-9:45am |
Refreshment Break |
| 9:45am-10:15am |
Extracellular vesicles deliver microRNA species to liver cancers in animal modelsFlorin M. Selaru, M.D., M.B.A. (Johns Hopkins Univ.) |
| 10:15am-10:30am |
Transcriptional reprograming that persists after clearance of oncogenic hepatitis C virusAtsushi Ono, M.D. (Mount Sinai) |
| 10:30am-10:45am |
The Cholangiocarcinoma Foundation PresentationStacie Lindsey, B.A., President and Founder |
| 12:00pm-1:15pm |
Conference Lunch |
SESSION 5: Genomics and Personalized Medicine for Primary Liver Cancers
Chairs: Josep M. Llovet, M.D., Xin Wei Wang, Ph.D..
Key Topic Areas: Focus will be on genomic analyses and informatics to identify signature gene expression profiles in the pathogenesis, molecular classifications, and personalized therapeutics of primary hepatobiliary cancers.
| Time | Presentation Title and Speaker* Ϯ |
| 1:30pm-2:00pm |
Molecular drivers and targeted therapies in HCCJosep M. Llovet, M.D. (Mount Sinai & Univ. Barcelona) |
| 2:00pm-2:30pm |
Using preclinical models to identify predictors of response to targeted therapeuticsRichard Finn, M.D. (UCLA) |
| 2:30pm-3:00pm |
Modeling and predicting metastasis in hepatocellular carcinomaDean W. Felsher, M.D., Ph.D. (Stanford Univ.) |
| 3:00pm-3:15pm |
Refreshment Break |
| 3:15pm-3:45pm |
Cancer genomic heterogeneity and integrated genomics to define primary liver cancersXin Wei Wang, Ph.D. (NCI-NIH) |
| 3:45pm-4:00pm |
Oncogenic NELFE enhances MYC-induced hepatocellular carcinogenesisHien Dang, Ph.D. (NCI-NIH) |
| 4:00pm-4:15pm |
The role of kinase fusion DNAJB1-PRKACA in fibrolamellar hepatocellular carcinomaYi Guo, Ph.D. (Mayo) |
| 4:15pm-4:30pm |
Blue Faery-The Adrienne Wilson Liver Cancer Association PresentationAndrea J. Wilson, MPW, ACC, President and Founder |
SESSION 6: Molecular Therapeutic Targeting of Hepatocellular and Cholangiocellular Carcinomas
Chairs: Lewis R. Roberts, M.B., Ch.B., Ph.D., Andrew X. Zhu, M.D., Ph.D..
Key Topic Areas: Focus will be on novel rational approaches for targeted therapies of hepatobiliary cancers, to include advances in immunotherapeutics and combinational treatment modalities.
| Time | Presentation Title and Speaker* Ϯ |
| 6:30pm-7:00pm |
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsAndrew X. Zhu, M.D., Ph.D. (Mass General, Harvard) |
| 7:00pm-7:30pm |
Immune based therapies: From mouse models to clinical trialsTim F. Greten, M.D. (NCI-NIH) |
| 7:30pm-8:00pm |
Glypican-3 as a liver cancer target for antibody- based therapiesMitchell Ho, Ph.D. (NCI-NIH) |
| 8:00pm-8:15pm |
Refreshment Break |
| 8:15pm-8:45pm |
Targeting the fibroblast growth factor receptor pathway in hepatobiliary cancersLewis R. Roberts, M.B., Ch.B., Ph.D. (Mayo) |
| 8:45pm-9:15pm |
Therapeutics for the pediatric cancer fibrolamellar hepatocellular carcinomaSanford M. Simon, Ph.D. (Rockefeller Univ.) |
| 9:15-9:30pm |
Closing RemarksAlphonse. E. Sirica, Ph.D., M.S. (VCU) |
| 6:30am-9:00am |
Conference Continental Breakfast |
| 9:00am |
Conference Ends |
*Oral presentations by Invited Speakers will be 25 minutes, with an additional 5 minutes for questions. Abstract-driven short talks will be 10 minutes, with 5 additional minutes for questions.
Ϯ Titles of individual oral presentations provided by the Invited Speakers are presumptive and may change to reflect new key basic and translational research findings and biomedical advances.
Photos:
Attendees List (updated 12/13/17)